Very Late HCV Relapse following Triple Therapy for Hepatitis C

Soriano V. , Vispo E. , de Mendoza C. Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C. Antivir Ther 2013; 18: 1033–1035.

Ghany M.G. , Nelson D. , Strader D. , Thomas D. , Seeff L. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433–1444.

Zeuzem S. , Heathcote E. , Shiffman M. Twelve weeks of follow-up is sufficient for the determination of sustained virological response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol 2003; 39: 106–111.

Medrano J. , Barreiro P. , Resino S. Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients. Clin Infect Dis 2009; 49: 1397–1401.

Manns M.P. , Pockros P. , Norkrans G. Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. J Viral Hepat 2013; 20: 524–529.

Hara K. , Rivera M. , Koh C. Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection? J Infect Dis 2014; 209: 38–45.

Zeuzem S. , Soriano V. , Asselah T. Interferon-free treatment with faldaprevir and BI 207127 for genotype 1 HCV infection. N Engl J Med 2013; 369: 630–639.

Lawitz E. , Poordad F. , Kowdley K. A Phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol 2013; 59: 18–23.